More spiked ED supplements recalled
This article was originally published in The Tan Sheet
Executive Summary
Los Angeles-based dietary supplement firms Barodon SF and Cosmos Trading voluntarily recalled products FDA found to contain aminotadalafil, an analogue of tadalafil, the active ingredient in Rx drugs used to treat erectile dysfunction. FDA told "The Tan Sheet" it detected the presence of the substance in the firms' products while testing "products promoted as dietary supplements for uses including enhanced sexual performance." The unapproved drugs marketed as supplements present a "threat to consumers because aminotadalafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels," FDA says. The agency prompted a recall of unapproved tadalafil-containing products in January (1"The Tan Sheet," Jan. 29, 2007, In Brief). Barodon announced its V.MAX recall on March 15, and Cosmos announced its Rhino Max recall on March 16...
You may also be interested in...
Liviro3 recall
Los Angeles-based Ebek says Jan. 19 it is issuing a voluntary nationwide recall of its supplement Liviro3 because the product contains tadalafil (Cialis), which is used to treat erectile dysfunction. Therefore, FDA says the product is an unapproved drug. FDA advised Ebek to recall the product because tadalafil may interact with nitrates found in prescription drugs and may lower blood pressure to dangerous levels. No illnesses have been reported to the company. In July 2006 an FDA survey found seven dietary supplements marketed to treat ED contained illegal drugs due to adulteration with active ingredients used in Rx ED treatments (1"The Tan Sheet," July 17, 2006, p. 4)...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.